OC
AGRX

Oppenheimer & Co’s Agile Therapeutics AGRX Stock Holding History

Oppenheimer & Co’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7
Closed -$42K – 1423
2020
Q3 		$42K Sell
7
-6
-46% -$34.4K ﹤0.01% 1265
2020
Q2 		$70K Buy
+13
New +$67.5K ﹤0.01% 1226

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Oppenheimer & Co's AGRX Position: Q4 2020 in Review

Oppenheimer & Co sold out of Agile Therapeutics (AGRX) in Q4 2020, closing a stake of 7 shares — an estimated $42K sold.

Oppenheimer & Co first reported a position in AGRX in Q2 2020 and held it in 2 quarters. The position peaked at $70K in Q2 2020. 76 funds tracked by Wall St. Rank hold AGRX as of Q4 2020.

  • Oppenheimer & Co reported no remaining Agile Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 7 Agile Therapeutics shares in Q4 2020, an estimated $42K.
  • Oppenheimer & Co first reported a position in Agile Therapeutics in Q2 2020 and held it in 2 quarters.
  • Oppenheimer & Co's Agile Therapeutics position peaked at $70K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2020.

Based on Oppenheimer & Co's 13F filing for Q4 2020, filed 11 Feb 2021.